FEATURED CONTRIBUTED CONTENT
Navigating the Complex Healthcare Landscape with a Strong 3PL Partner
In this episode, we discuss the timing for planning your commercial strategy, key items in selecting a distribution partner, the most beneficial value-added services in a logistics plan, and business growth beyond the product launch.
Providing effective support for people living with cancer: Insights from health psychology
Dr. Laura Moore discusses the concept of “chronic cancer,” and the changing treatment landscape. She talks about the challenges in supporting people as they adjust to a cancer diagnosis and engage in self-management of their illness, including treatment adherence. She explains how ongoing education and personalized support can help individuals across their treatment experience. The […]
How Technology is Reshaping the Rare Disease Landscape
Technology is transforming clinical drug development. In the rare disease space, clinical drug development is moving away from traditional approaches that rely on patients to travel long distances to clinical sites and toward a more patient-focused paradigm. This new paradigm is especially suited to studies in patients with rare diseases; these studies target small populations of geographically dispersed patients […]
Supporting adherence to oral anticancer treatments: Key components of successful adherence interventions
Oral anticancer medicines are well established in healthcare, shifting greater responsibility on the patient to self-manage their treatment. Yet, a recent literature review showed adherence rates to oral anticancer treatments are as low as 40%. While there is a range of supportive services for individuals living with cancer, there is relatively little support that addresses […]
Addressing Unmet Needs of Patients and Providers in Rare and Complex Disease
As the growth of rare and complex disease continues to skyrocket, more than ever, pharmaceutical manufacturers must address the unique challenges of providers and their patients to differentiate their brand. Providers and their staff have a lack of knowledge; they face continued time constraints, and with the growth of new products it’s difficult to keep […]
Unlocking the potential of online communities – looking beyond the surface
While online communities have emerged as a critical component of understanding the experiences of people living with chronic conditions, there is so much more to learn and uncover beneath the surface. In this webinar, Health Union, a pioneer in creating open, online health communities (19 and counting), including migraine.com, multiplesclerosis.net and lungcancer.net, discusses the how […]
Clinical Trials in Children with Impaired Mental Capacity
In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, complex situations do arise. Pediatric clinical trials present unique challenges, as do those in patients who lack legal competence. In the instance of a mentally impaired child, it is important to determine the best approach for obtaining consent and assent as early as possible […]
The Power of Insight
Good insight gives you the tools to create innovative products and services that meet customers’ needs at the point of need, transforming lives. However, many organisations find distilling large swathes of data into meaningful insights challenging. Download the white paper to learn: Tools for easily bringing your research to life How to turn data into […]
Precision Medicine: A Glossary of Terms
As genetic testing becomes increasingly common as an integral part of clinical development programs, understanding the key terms and definitions is essential for all members of research and clinical development teams. Download this glossary of commonly used terms in Precision Medicine to gain an understanding of commonly-used terms in the discussion of genetics, genetic testing, […]
The EU HTA Harmonization Initiative: What is the Significance to Manufacturers of the New Directive?
Comparative clinical benefit assessments are at the core of Health Technology Assessments (HTAs) in Europe. HTAs are a multi-disciplinary process considering input and evidence from medical, social, and economic sources. They are used to inform the design of health policies that allow the safe and effective use of new technologies within individual health systems and […]
The Future of Work is Now. Are you Ready?
In today’s rapidly changing market, organizations and workforce experts alike are trying to determine how the future of work will transform. Based on conversations across the market and our in-depth research, KellyOCG has determined that there are four dimensions organizations need to consider when contemplating the “Future of Work”: technology, the workforce (including the multiple […]
Adapting the Functional Services Model to Deliver Flexible Solutions
A mid-sized multinational client had historically resourced its monitoring services with multiple providers, including Covance, but wanted to move to one preferred partner for each of its global regions with a Functional Service Provider (FSP) model.
Medical Storytelling: Combining High Science and High Emotion for High Impact
During this presentation, the speakers will share their insights on transforming medical education content from a package insert rehash into a compelling, compliant medical story. They will highlight how you can take healthcare provider audiences from being passive listeners to active participants by Capturing and keeping their attention, reception, and recall Provocatively challenging healthcare providers […]
Cross-Border Enrollment of Rare Disease Patients
Clinical trials in rare diseases present unique challenges unseen in trials for more common conditions. Rare disease patient populations are inherently small, and prospective participants are widely dispersed. Likewise, the number of clinical research sites with such specialized experience is limited. These issues can be mitigated by enrolling patients who are not residents of the […]
Building a Secure, Automated Quality System to Accelerate Time to Market
Today life science companies face a perfect storm of factors driving their costs up and sales down. With 40% of R&D costs linked to paper-based processes, legacy, manual processes pose a particular threat – costing life science companies billions of dollars a year and delaying product launch and commercialization*. Boston Scientific is tackling these challenges […]
Clinical Trials in Children with Impaired Mental Capacity
PRA has written a new white paper on conducting clinical trials with adolescents, specifically children with impaired mental capacity. In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, we do conduct studies in patients who lack legal competence. This occurs most frequently in pediatric patients; in these cases the lack of […]
How Technology is Reshaping the Rare Disease Landscape
PRA has recently released a white paper about technology’s effects on rare disease research. Approximately 7,000 rare diseases affect an estimated 350 million people worldwide, and with diagnostic advances, new diseases are discovered every day. Although the number of clinical trials in rare diseases has increased by 56% in the last 3 years, only 5% of rare diseases […]
Prescribe Robust Distribution to Commercialize Your Orphan Drug
Finding a home for your biopharmaceutical company’s new orphan drug doesn’t just happen after it is FDA approved. The successful commercialization of your promising new drug requires a focused and well-planned distribution model. But first, some background. Orphan drugs treat rare diseases or medical conditions that affect fewer than 200,000 people a year in the […]
Cross-Border Enrollment of Rare Disease Patients
PRA has written a new white paper on the considerations for planning and conducting global rare disease clinical trials. Rare disease trials are inherently designed to include fewer patients, are often longer in duration, and more frequently terminated than trials in more common indications. These challenges impact both sponsors and patients. A recent literature review […]
